# cAMeLot-2 (NCT06852222)

> A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

No report yet. It can be ordered.

- Drugs tested: bleximenib

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06852222
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Leukemia, Myeloid, Acute
- Interventions: Bleximenib; Venetoclax (VEN); Azacitidine (AZA); Placebo
- Enrollment: 600
- Primary outcome: Percentage of Participants who Achieve Complete Remission (CR)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on cAMeLot-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- Podcasts: 2
- X threads: 1
- X videos: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=camelot-2-nct06852222